MDT Q2'26 Earnings: revenue estimate is 9.48B USD

Medtronic (MDT) is scheduled to release Q2'26 earnings on November 24, with estimated revenue of $9.48B and EPS of $1.33. Results will be announced at 6:45 AM ET.

Original reporting
Published Nov 17, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MDT Q2'26 Earnings: revenue estimate is 9.48B USD — source image
Decision brief

The 30-second read

$MDTNeutralMed
01

Why it matters

The provided consensus revenue and EPS create a reference point for traders to gauge whether the eventual report is likely to beat or miss, but no new company-specific information is disclosed yet.

02

Market read

Useful for timing and expectation-setting ahead of the earnings release, but it is not a first report of new fundamentals.

03

What to watch

Actual price reaction will depend on guidance, margins, and segment trends, none of which are disclosed here.

Relevance 4/10Novelty 3/10Timing: Nov 24 pre-market earnings release (expected at 6:45 AM ET)

Background

The article is a pre-earnings setup for Medtronic’s Q2'26 results, scheduled for Nov 24 before the market opens.

Company-level read

Ticker impact

$MDTNeutralMedium confidence
Context

Medtronic is scheduled to report Q2'26 results Nov 24, with consensus revenue of $9.48B and EPS of $1.33.

Expected impact

Likely volatility into the Nov 24 pre-market earnings window as the market compares the actual print to the provided consensus figures.

Evidence & confidence

The article provides a scheduled earnings date and consensus estimates, but it does not include any surprise, guidance change, or newly disclosed company-specific development.

Market effects

A large medtech earnings event can influence near-term sentiment and positioning across medical devices, but the article itself is only a scheduling/consensus setup.

Primarily impacts US-listed medtech trading around the pre-market earnings window.

Limited global spillover from a single-company earnings date and consensus estimates.

Counterpoint

Because the piece only states consensus expectations and timing, it may not justify new positioning beyond normal earnings-volatility management.

Key entities

  • Medtronic plc.

    Subject of the earnings preview, scheduled to report Q2'26 results on Nov 24 before the market opens.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.